成人急性髓系白血病巩固治疗中伊达比星剂量递增研究
本研究将诱导缓解后的成人急性髓系白血病患者随机分配接受标准剂量或强化剂量伊达比星巩固治疗,主要终点为无白血病生存期。强化组3年无白血病生存率显著优于标准组,但完成计划巩固治疗的比例较低,非血液学毒性无差异。
要点
- 强化组3年无白血病生存率为47%,标准组为35%,差异有统计学意义(P=0.045)。
- 强化组完成计划巩固治疗的比例为65%,低于标准组的82%(P<0.001)。
- 两组严重非血液学毒性无差异,但强化组严重中性粒细胞减少和血小板减少持续时间延长。
核心结论
- 成人急性髓系白血病巩固治疗中增加伊达比星累积剂量可改善无白血病生存期,且不增加非血液学毒性。
研究设计与样本
- 随机对照试验,纳入293例16至60岁、排除核心结合因子急性髓系白血病和急性早幼粒细胞白血病的完全缓解患者,标准组146例,强化组147例。
主要发现
- 中位随访5.3年(范围0.6至9.9年),强化组3年无白血病生存率为47%(95%CI 40%至56%),标准组为35%(95%CI 28%至44%),P=0.045。
- 5年总生存率强化组为57%,标准组为47%,P=0.092。
- 标准组120例(82%)完成计划巩固治疗,强化组95例(65%)完成计划巩固治疗,P<0.001。
- 强化组严重中性粒细胞减少和血小板减少持续时间延长,但严重非血液学毒性无差异。
- 在细胞遗传学或FLT3内部串联重复和NPM1基因突变亚组中,未发现强化巩固治疗的选择性获益证据。
关键数值与推荐
- 巩固治疗方案:阿糖胞苷100 mg/m2每日,共5天;依托泊苷75 mg/m2每日,共5天;伊达比星9 mg/m2每日,标准组用2天,强化组用3天;共2个周期。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Higher doses of the anthracycline daunorubicin during induction therapy for acute myeloid leukemia (AML) have been shown to improve remission rates and survival. We hypothesized that improvements in outcomes in adult AML may be further achieved by increased anthracycline dose during consolidation therapy. Patients and Methods Patients with AML in complete remission after induction therapy were randomly assigned to receive two cycles of consolidation therapy with cytarabine 100 mg/m2 daily for 5 days, etoposide 75 mg/m2 daily for 5 days, and idarubicin 9 mg/m2 daily for either 2 or 3 days (standard and intensive arms, respectively). The primary end point was leukemia-free survival (LFS). Results Two hundred ninety-three patients 16 to 60 years of age, excluding those with core binding factor AML and acute promyelocytic leukemia, were randomly assigned to treatment groups (146 to the standard arm and 147 to the intensive arm). Both groups were balanced for age, karyotypic risk, and FLT3-internal tandem duplication and NPM1 gene mutations. One hundred twenty patients in the standard arm (82%) and 95 patients in the intensive arm (65%) completed planned consolidation ( P < .001). Durations of severe neutropenia and thrombocytopenia were prolonged in the intensive arm, but there were no differences in serious nonhematological toxicities. With a median follow-up of 5.3 years (range, 0.6 to 9.9 years), there was a statistically significant improvement in LFS in the intensive arm compared with the standard arm (3-year LFS, 47% [95% CI, 40% to 56%] v 35% [95% CI, 28% to 44%]; P = .045). At 5 years, the overall survival rate was 57% in the intensive arm and 47% in the standard arm ( P = .092). There was no evidence of selective benefit of intensive consolidation within the cytogenetic or FLT3-internal tandem duplication and NPM1 gene mutation subgroups. Conclusion An increased cumulative dose of idarubicin during consolidation therapy for adult AML resulted in improved LFS, without increased nonhematologic toxicity.
引用
- Bradstock KF, Link E, Di Iulio J, et al. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. J Clin Oncol. 2017. PMID: 28368672. doi:10.1200/JCO.2016.70.6374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。